Compare Ginkgo Bioworks Holdings Inc (DNA) vs General Mills, Inc. (GIS) Price & Performance

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

General Mills (GIS) trades at $31.77, down 1.27% with bearish technical signals despite beating Q2 2026 EPS estimates. The stock shows attractive valuation metrics with P/E of 9.23 and P/S of 0.96, but faces fundamental challenges including negative net income margin of -4.89% and declining revenue trends from $19.5B in 2025 to projected $18.3B in 2026. Recent CEO transition to Dana McNabb and dividend stability at $0.61 quarterly provide some stability amid operational headwinds.

The outlook remains cautious with Wall Street showing mixed sentiment - 61% hold ratings but $36 consensus target suggests 13% upside. Key risks include ongoing margin pressure, competitive threats in packaged foods, and macroeconomic sensitivity. The high 7% dividend yield offers income appeal but sustainability concerns persist given negative profitability metrics and cash flow challenges.